Clinical trials: Metastatic Esophageal Cancer
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell…
- Conditions
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT01598077
- Testing
- LJM716
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Advanced Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma).
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT07432295
- Testing
- Givastomig, Nivolumab, 5Fluorouracil
- Where
- 6 sites in United States, China and 1 more
- Volunteers
- 180 people
- Sponsor
- I-Mab Biopharma US Limited
Esophageal Cancer
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00861094
- Testing
- cisplatin, 5-FU, oxaliplatin
- Where
- 28 sites in France
- Volunteers
- 266 people
- Sponsor
- UNICANCER
Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer, Stage IV Esophageal Cancer
- Trial name
- NCT00077545
- Testing
- triapine, cisplatin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Oesophageal Carcinoma
A Study of APR-246 in Oesophageal Cancer
The purpose of this study is to determine whether APR-246, 5-FU and cisplatin are safe and effective in the treatment of platinum resistant oesophageal cancer.
- Trial name
- APROC (NCT02999893)
- Testing
- APR-246
- Where
- 5 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Esophageal Cancer
Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus
RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients who have cancer of the esophagus.
- Trial name
- NCT00003321
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 10 sites in Australia, France and 6 more
- Volunteers
- 370 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Cancer
Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238407
- Testing
- Docetaxel and Cisplatin, Radiotherapy
- Where
- 10 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Swiss Cancer Institute
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Esophageal Cancer
Optimal Nutritional Palliation of Obstructed GEJ Cancer
The main goal of this trial is to assess whether it's feasible to conduct a larger, full-scale study comparing the use of gastrostomy (g-tubes) and stents in patients with unresectable cancer of the stomach and/or esophagus, and…
- Trial name
- NCT06876454
- Testing
- Gastrostomy Tube, Self Expanding Metal esophageal Stent
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Radiotherapy, Metastatic Solid Cancers
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Preclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors…
- Conditions
- Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
- Trial name
- ILDR-02 (NCT07071103)
- Testing
- Low-dose radiotherapy to the intestine (ILDR), PD-1/PD-L1 monoclonal antibodies
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chuangzhen Chen
Esophageal Cancer, Cancer of the Esophagus
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
The investigators propose to treat patients with metastatic esophageal cancers and dysphagia with two fractions of brachytherapy followed by pembrolizumab.
- Trial name
- NCT02642809
- Testing
- Pembrolizumab, Brachytherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Toxicity
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
Oesophagogastric cancer is a major cause of cancer related mortality, with an overall 5-year survival rate of 10% worldwide and patients are often diagnosed with locally advanced or metastasized disease at first presentation.
- Trial name
- ACTION (NCT02273713)
- Testing
- Nab-paclitaxel
- Where
- Netherlands
- Volunteers
- 154 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)